![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 52, 50959-50965, December 27, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
and
§¶
From the Departments of
Pediatrics and
§ Cell and Developmental Biology, Division of
Gastroenterology, Hepatology, and Nutrition, Vanderbilt University
School of Medicine, Nashville, Tennessee 37232
Received for publication, July 15, 2002, and in revised form, October 4, 2002
| |
ABSTRACT |
|---|
|
|
|---|
Probiotic bacteria are microorganisms that
benefit the host by preventing or ameliorating disease. However,
little information is known regarding the scientific rationale for
using probiotics as alternative medicine. The purpose of this paper is
to investigate the mechanisms of probiotic beneficial effects on
intestinal cell homeostasis. We now report that one such probiotic,
Lactobacillus rhamnosus GG (LGG), prevents cytokine-induced
apoptosis in two different intestinal epithelial cell models. Culture
of LGG with either mouse or human colon cells activates the
anti-apoptotic Akt/protein kinase B. This model probiotic also inhibits
activation of the pro-apoptotic p38/mitogen-activated protein kinase by
tumor necrosis factor, interleukin-1 The human gastrointestinal microflora establishes at birth and
acquires through a series of colonizations more than 400 bacterial species in the adult (1). Recent evidence clearly demonstrates that
commensal bacteria regulate intestinal epithelial development and
function (2, 3), and interruption of these interactions results in
pathological conditions. Probiotics, as described by Lilly and
Stillwell (4), are living microorganisms with low or no pathogenicity
that exert beneficial effects on the health of the host. In human
clinical trials the non-pathogenic Gram-positive commensal
Lactobacilli found in the human and mouse gastrointestinal tracts have been considered as probiotics with beneficial health effects, including enhanced lymphocyte proliferation (5), innate and
acquired immunity (6), and anti-inflammatory cytokine production (7).
Lactobacillus rhamnosus GG
(LGG),1 a bacterium used in
the production of yogurt, is one of the best-studied probiotic bacteria
in clinical trials. It is effective in preventing and treating diarrhea
(8), recurrent Clostridium difficile (9), primary rotavirus
infections (10), and atopic dermatitis (11). Therefore, manipulation of
enteric microflora by selective living microorganisms termed probiotics
are promoted by practitioners of alternative health measures.
There is increasing evidence that probiotic Lactobacillus
species play a role in the treatment of inflammatory bowel disease (IBD). In this disease, abnormal immune responses cause inflammation that appears to be stimulated by elements of the enteric
microenviroment, including normal and pathogenic organisms (12).
Reduction of Lactobacillus and Bifidobacteria has
been found in colonic biopsies of patients with IBD (13, 14). Although
conventional therapeutic strategies focus on suppression or modulation
of host immunity, modification of enteric microflora by probiotics may
have a role in treating IBD. Several Lactobacillus strains
prevent or attenuate intestinal inflammation in the interleukin
(IL)-10 Putative mechanisms of the action of probiotics include regulation of
cytokine production (18), such as stimulation of mononuclear cells to
generate both pro- and anti-inflammatory cytokines (19, 20),
enhancement of secretory IgA secretion (21), production of
antibacterial substances (22, 23), an increase in the integrity of the
intestinal barrier (24), and competition with pathogenic microorganisms
for enterocyte binding (25). Yet almost nothing is known regarding the
basic molecular mechanisms of probiotic regulation of intestinal
epithelial health.
Two common features of IBD involve increased cytokine production (26,
27) and increased apoptosis of intestinal cells (28). We have reported
that a central cytokine in the pathogenesis of IBD, tumor necrosis
factor (TNF) (27), regulates both anti- and pro-apoptotic signaling
pathways, and the balance between these two kinds of signals determines
the cell fate (29). Therefore, the purpose of the present study is to
investigate the effects of LGG on cytokine-regulated signaling pathways
determining intestinal cell fate.
We now report that LGG prevents cytokine-induced apoptosis in
mouse or human intestinal epithelial cells. Culture of LGG with colon
cells activates the anti-apoptotic Akt/protein kinase B. Further, this
model probiotic inhibits activation of the pro-apoptotic p38/mitogen-activated protein (MAP) kinase by TNF, IL-1 Bacterial Culture and Supernatant Preparation--
LGG (American
Type Culture Collection 53103) was incubated in
Lactobacillus MRS broth at 37 °C for 24 h, then
diluted in MRS broth, and incubated at 37 °C to reach log phase with
the density determined as 0.5 at A600 (20). LGG
was precipitated from MRS broth (1000 × g, 15 min) and
washed twice with phosphate-buffered saline. Heat-killed (hk) LGG was
prepared by boiling LGG in phosphate-buffered saline for 1 h and
then washing it with phosphate-buffered saline. Lactobacillus
acidophilus (American Type Culture Collection 393) and
Lactobacillus casei (American Type Culture Collection 4356) were cultured per ATCC guidelines. 107
colony-forming units/ml LGG, L. casei, or L. acidophilus in RPMI cell culture medium were used to treat cells.
Salmonella pullorum (provided by Andrew Neish, Emory
University, Atlanta, GA) was prepared and incubated with cells as
described (30).
Supernatant recovered from LGG culture broth (LGG-s) was generated by
centrifuging (1000 × g, 15 min) and filtering (0.2 µm) LGG culture in MRS broth; then the filtrate was concentrated
using Centricon Plus-20 (5-100 kDa, Millipore, Bedford, MA) by
centrifugation (4000 × g, 1 h) following
guidelines from the manufacturer. Protein concentrations were
determined by DC protein assay (Bio-Rad) using MRS broth as the
control. LGG-conditioned cell culture medium (LGG-cm) was generated by
incubating washed LGG (107 colony-forming units/ml) in RPMI
cell culture medium at 37 °C for 2 h; the medium was
centrifuged twice (1000 × g, 15 min) and then filtered
(0.2 µm).
Cell Culture--
Young adult mouse colon (YAMC) cells were
grown in RPMI with 5% fetal bovine serum on collagen-coated culture
dishes as described previously (31). Clonal cell lines stably
expressing pFLAG-cDNA3-kinase-inactive (ki) kinase suppressor of
Ras (KSR) or pFLAG-cDNA3-wild-type KSR (provided by Richard
Kolesnick, Memorial Sloan-Kettering Cancer Center, New York, NY) were
generated as described (32). The kiKSR plasmid expresses a
kinase-inactive dominant-negative KSR as previously described (32, 33).
Clonal cells were cultured in the presence of G418 (100 µg/ml) until
24 h prior to the experiments. The human colonic epithelial
carcinoma cell line, HT 29 cells, was grown in Dulbecco's modified
Eagle's medium supplemented with 10% fetal bovine serum. All cells
were serum-starved (0.5%) at 37 °C for 24 h before experiments.
Preparation of Cellular Lysates--
Lysates were prepared from
cells treated with murine TNF, IL-1 Apoptosis Assay--
YAMC and clonal cell lines were cultured on
collagen-coated or HT29 cells on non-coated chamber glass slides and
were prepared as described above. Following treatment, apoptotic cells
were labeled by ApopTag in situ apoptosis detection kits
(Intergen, Purchase, NY) using terminal deoxynucleotidyltransferase for
detection of positive cells following guidelines from the manufacturer. Apoptotic cells were labeled by fluorescein
isothiocyanate-conjugated anti-digoxigenin or anti-digoxigenin
peroxidase conjugate and 3,3'-diaminobenzidine as substrate and were
then dehydrated and mounted using Vectashield mounting medium. Slides
were counterstained with 4,6-diamidino-2-phenylindole (DAPI) by using 1 µg/ml DAPI in mounting medium. The cells were observed by
fluorescence microscopy or differential interference contrast.
Apoptotic terminal deoxynucleotidyltransferase-mediated dUTP
nick-end-labeling (TUNEL) positive cells were determined by
counting at least 200 cells in randomly chosen fields and expressing them as a percentage of the total number of cells counted.
Caspase activity was detected in living cells using the sulforhodamine
multi-caspase activity kit (Biomol) following guidelines from the
manufacturer. Active caspase enzyme in living cells was labeled with
cell-permeable sulforhodamine-conjugated valylalanylaspartic acid
fluoromethyl ketone, an inhibitor of caspase activity that binds to
active caspase enzyme. Cells with increased caspase activity were
detected by fluorescence microscopy.
LGG Prevents Cytokine-induced Apoptosis in Intestinal Epithelial
Cells--
Pathological concentrations of TNF inhibit intestinal cell
proliferation without inducing apoptosis in YAMC cells (29, 31). Because dominant-negative kiKSR expression induces apoptosis in TNF-treated intestinal cells (29), we used kiKSR-expressing colon cells
to test our hypothesis that probiotics prevent TNF-induced apoptosis
through regulation of signal transduction pathways. We found that
TNF-stimulated apoptosis detected by TUNEL staining in kiKSR-expressing
YAMC cells was inhibited by co-culture with viable LGG but was not
hkLGG (Fig. 1, A and
B). Furthermore, in a model of human intestinal cell
apoptosis the effect of a "cytokine mixture" combination of TNF,
IL-1 LGG Regulates Signaling Pathways That Determine Cell Fate--
The
balance between anti-apoptotic and pro-apoptotic signal transduction
pathways regulates the fate of cells exposed to various stimuli
including TNF. Therefore, we studied the effects of LGG on signal
transduction pathways that regulate cell fate. LGG or LGG-cm, but not
heat-killed LGG, stimulates anti-apoptotic Akt activation determined by
antibody against Ser(P)-473-Akt (Fig. 2A). Akt activation is also
enhanced by LGG-s in a concentration-dependent manner (Fig.
2, B and C). This activation by either LGG or TNF is blocked by the PI 3-kinase inhibitors, LY294002 or wortmannin, but
not by the MEK1 inhibitor, PD98059 (Fig. 2D). Whereas kiKSR expression inhibits TNF activation of Akt, both LGG and
LGG-cm stimulate Akt phosphorylation in these cells (Fig.
2E), indicating that TNF and LGG utilize different
mechanisms to activate PI 3-kinase upstream of Akt. Nuclear factor (NF)
By using an antibody to phospho-p38 we determined that viable LGG
inhibits TNF-induced activation of this pro-apoptotic MAP kinase
(Fig. 3, A-C). Unlike Akt
activation, inhibition of p38 is not reproduced by factors present in
LGG-cm (Fig. 3, A and B). The cytokine-activated
pro-apoptotic SAPK/JNK activities are not affected by LGG (Fig.
3D). Collectively these data indicate that LGG promotes
survival of intestinal epithelial cells exposed to inflammatory
cytokines through activation of specific anti-apoptotic and inhibition
of pro-apoptotic signals.
Probiotic Bacterium Regulation of Cell Survival Is
Strain-specific--
These findings raise an important question. Is
this anti-apoptotic response unique to LGG, or is it common to other
probiotic commensal or non-pathogenic intestinal microflora? To address this question we studied the effects of two other Gram-positive strains
of Lactobacillus, L. acidophilus and L. casei, known to enhance lymphocyte proliferation and immunity (5,
6) or macrophage activation (34), respectively. Whereas these two bacteria stimulate Akt activation, they show no inhibition of TNF-stimulated p38 (Fig. 4A).
Accordingly, their inhibitory effect on TNF-induced apoptosis is
significantly reduced compared with LGG (Fig. 4B).
Furthermore, we studied two Gram-negative bacteria derived from colon
flora isolates, Salmonella typhimurium
PhoPc and S. pullorum, that have been
shown to regulate TNF-stimulated signal transduction pathways in
intestinal cells (30). Neither of these attenuate TNF-induced apoptosis
in colon cells (Fig. 4, C and D). Therefore,
reversal of cytokine-induced apoptosis by LGG does not extend to all
commensal or non-pathogenic intestinal microflora. This evidence
suggests that a need for caution in selecting "probiotics" for
clinical study is warranted and may explain variability in results of
clinical trials investigating different probiotics.
Akt and p38 MAP Kinase Determine the Fate of Intestinal Epithelial
Cells Exposed to TNF--
To determine the relative importance of Akt
activation and inhibition of p38 activity in regulating the fate of
intestinal cells exposed to TNF, we used pharmacological inhibitors. A
blockade of Akt activation by PI 3-kinase inhibitors (as shown in Fig. 2D) increases apoptosis in YAMC cells treated with TNF (Fig.
5, A and B),
whereas inhibitors of p38 block apoptosis in TNF-treated kiKSR-expressing cells (Fig. 5, C and D). As
expected, both p38 inhibitors reduce p38 activation at concentrations
that were studied (Fig. 5E). These results are consistent
with the hypothesis that activation of Akt and inhibition of p38 by LGG
are central to its anti-apoptotic effect.
The lumen of the gastrointestinal tract has evolved with a complex
ecosystem that includes commensal and pathogenic bacteria with the
capability of cross-species communication (3, 35). Lilly and Stillwell
(4) described microbes that had potential benefit to their hosts as
probiotics. We have studied the relationships between
Lactobacillus GG, as a model probiotic, and the intestinal epithelial cell, the point of first contact with the host. Our novel
findings demonstrate that LGG promotes the survival of
intestinal epithelial cells through the activation of the
anti-apoptotic Akt/protein kinase B and inhibition of the pro-apoptotic
p38 MAP kinase. LGG produces a factor that activates Akt independent of bacterial cellular interaction.
It is possible that other commensal organisms with potential probiotic
activity (6, 30, 36, 37) could prevent cytokine-induced apoptosis.
Although some of those we tested reduced apoptosis, none were as
effective as LGG, and LGG appeared unique in its ability to block p38
MAP kinase activation. These findings extend our understanding of the
complexity of the host commensal relationship and suggest that
intestinal cell survival in its cytokine-rich environment may be
regulated by the presence of beneficial microbes. This effect appears
to require live bacteria, because either heat treatment (Figs. 2 and 3)
or glutaraldehyde fixation (data not shown) prevents LGG regulation of
Akt or p38 MAP kinase.
The mechanisms by which intestinal bacteria modulate the inflammatory
process are complex and incompletely understood. Probiotic bacteria
interact with three components of the gastrointestinal tract including
intestinal epithelial cells, luminal flora, and the mucosal immune
cells. It is known that probiotic bacteria can regulate lymphocyte
cytokine production (18-20). Nonpathogenic Salmonella
species can regulate the immune response by blocking NF Our current understanding of cell survival suggests that the balance
between pro-apoptotic and anti-apoptotic signals generated by cytokines
regulates apoptosis (39). Anti-apoptotic signaling pathways initiated
by TNF, other cytokines, and growth factors include NF Surprisingly, factors recovered from bacterial culture or conditioned
cell culture media reduce apoptosis and activate Akt. Production of
these factors does not require bacterial-intestinal cell contact.
Previously studies have reported that some Lactobacillus strains produce proteinaceous (23) or protease-insensitive (22) anti-bacterial compounds. However, we are unaware of reports
indicating that bacterially produced factors regulate either Akt signal
transduction or cell survival pathways. Thus far we have identified two
proteins in LGG culture broth with molecular sizes of ~80 and 42 kDa
based on SDS-PAGE. These two factors are heat- and protease-sensitive, and their activities are recoverable by electroelution from
polyacrylamide gels (data not shown). Clearly, recovery and further
characterization of these factors is a high priority.
Our evaluation of LGG as a model probiotic organism reveals an
important and novel relationship between intestinal epithelial cell
survival and selective microflora. Clearly, this single epithelial layer lining the intestine exists in a relatively hostile environment of pathogenic organisms, toxic waste by-products, and cytokines. This
report adds to our understanding of the signal transduction pathways in
the intestinal epithelial cell that are regulated by probiotics and
commensal organisms to include intestinal cell survival in
addition to intestinal homeostasis (3, 30). Therefore, further studies
of the molecular basis for probiotic regulation of intestinal
epithelium are relevant to understanding normal development as well as
the pathogenesis of inflammatory bowel disease.
, or
-interferon.
Furthermore, products recovered from LGG culture broth supernatant show
concentration-dependent activation of Akt and inhibition of
cytokine-induced apoptosis. These observations suggest a novel
mechanism of communication between probiotic microorganisms and
epithelia that increases survival of intestinal cells normally found in
an environment of pro-apoptotic cytokines.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
/
mouse model, which spontaneously develops
enterocolitis (15, 16). LGG increases anti-inflammatory IL-10 levels in
children (7). Furthermore, LGG has been suggested as adjunctive therapy for Crohn's disease (17).
, or
-interferon (IFN). Therefore, LGG promotes intestinal epithelial
cell survival through regulation of both anti- and pro-apoptotic signal
transduction pathways. These novel observations provide insight into
the rationale for LGG as a potential treatment for IBD.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
, or
-IFN (Pepro Tech, Inc.,
Rocky Hill, NJ) for the indicated times in the presence or absence of
LGG, LGG-s, LGG-cm, hk-LGG, phosphoinositide (PI) 3-kinase inhibitors,
wortmannin (Sigma) or LY294002 or p38 inhibitors (Biomol, Plymouth
Meeting, PA) SB203580 or SB202190. Cell monolayers were washed twice
with ice-cold phosphate-buffered saline and then scraped into cell
lysis buffer (20 mM HEPES (pH 7.5), 1 mM
orthovandate, 50 mM
-glycerophosphate, 10 mM
sodium pyrophosphate with leupeptin (10 µg/ml), aprotinin (10 µg/ml), phenylmethylsulfonyl fluoride (18 µg/ml), and 1% Triton
X-100). The scraped suspensions were centrifuged (14,000 × g, 10 min) at 4 °C, and protein content was determined
using DC protein assay (Bio-Rad). Equal amounts of cellular lysate
protein were mixed with Laemmli sample buffer and separated by SDS-PAGE
for Western blot analysis with anti-phospho-Akt, anti-Akt,
anti-phospho-p38, anti-p38, anti-I
B
, anti-phospho
stress-activated protein kinase/c-Jun amino-terminal kinase (SAPK/JNK),
anti-SAPK/JNK (Cell Signaling Technology, Beverly, MA), or anti-phospho
extracellular signal-regulated kinase (ERK)1/ERK2/MAP kinase (Promega,
Madison, WI) antibodies.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
, and
-IFN is reversed by LGG (Fig. 1D). DAPI
staining shows nuclear condensation of the TUNEL-positive intestinal
cells undergoing apoptosis (Fig. 1A). To further demonstrate that the observed LGG effect is caused by the inhibition of apoptosis, we used a multi-caspase activity assay in living cells. The increased caspase activity of cells undergoing apoptosis is blocked by viable LGG
(Fig. 1C). Interestingly, cell survival is also enhanced by LGG-s, and this inhibitory effect on apoptosis is
concentration-dependent (Fig. 1, A-D).

View larger version (23K):
[in a new window]
Fig. 1.
LGG inhibits cytokine-induced apoptosis in
intestinal epithelial cells. kiKSR-expressing YAMC cells
(A-C) or human colonic epithelial carcinoma cell
line (HT29) cells (D) were treated with TNF (100 ng/ml) or the "cytokine mixture" combination of TNF (100 ng/ml),
IL-1
(10 ng/ml), and
-IFN (100 ng/ml), respectively, for 6 h
in the presence or absence of a 1-h pretreatment with viable LGG,
hk-LGG, or concentrated supernatant recovered from LGG
culture MRS broth (LGG-s) at the concentrations indicated.
Then, cells were fixed for terminal deoxynucleotidyltransferase TUNEL
with apoptotic nuclei labeled with fluorescein isothiocyanate and DAPI
staining (A and D). Fluorescein isothiocyanate-
and DAPI-labeled images were taken from the same field. The percentage
of cells undergoing apoptosis from a representative experiment is shown
in B. Caspase activity in living cells was detected using a
multi-caspase activity assay kit (C). Arrows
indicate representative apoptotic nuclei. All experiments in this and
subsequent figures were performed on at least three separate
occasions.
B and ERK/MAP kinase activation are important TNF-activated
antiapoptotic signal transduction pathways in intestinal cells (29).
TNF stimulates both degradation of the inhibitor of
B and activation
of ERK1/ERK2. However, LGG does not effect activation of either of
these anti-apoptotic molecules (Fig. 2F), which indicates
that LGG inhibition of TNF-induced apoptosis is not caused by the
disruption of TNF receptor binding activities.

View larger version (33K):
[in a new window]
Fig. 2.
LGG or factors recovered in LGG-cm or LGG-s
stimulate Akt activation. YAMC (A, B,
D, F), HT29 (C), and kiKSR-expressing
cells (E) were treated with viable LGG, hk-LGG, LGG-cm, or
LGG-s as indicated for 1 h followed by TNF (100 ng/ml, 15 min)
treatment. PI 3-kinase inhibitors, wortmannin (100 nM) or
LY294002 (10 µM), or MEK1 inhibitor PD98059 (10 µM) was used to pre-treat cells for 1 h before TNF
or LGG treatment (D). Akt activation was detected by Western
blot analysis of cellular lysates with anti-Ser(P)-473-Akt and anti-Akt
antibodies. YAMC cells were treated with LGG for the indicated times,
and I
B
degradation and ERK1/2 activation were detected by Western
blot analysis of cellular lysates with anti-I
B
or anti-phospho
(P) ERK1/2 antibodies (F).

View larger version (42K):
[in a new window]
Fig. 3.
LGG blocks cytokine-induced p38
phosphorylation. YAMC (A, D), kiKSR
(B), or HT29 (C) cells were treated with TNF (100 ng/ml), IL-1
(10 ng/ml), or
-IFN (100 ng/ml) as indicated in the
presence or absence of a 1-h pretreatment with viable LGG, hk-LGG, or
LGG-cm. Cellular lysates were prepared for Western blot analysis with
anti-Thr(P)-p38, anti-p38, anti-phospho-SAPK/JNK, and anti-SAPK/JNK
antibodies.

View larger version (46K):
[in a new window]
Fig. 4.
Regulation of signal transduction and
apoptosis in intestinal cells by commensal or non-pathogenic
bacteria. YAMC cells were treated with LGG, L. casei
(LC), or L. acidophilus (LA) for
1 h followed by 15 min of TNF (100 ng/ml) treatment as indicated
in A. Akt and p38 activation was detected as before. LC, LA
(B), or S. pullorum (C and
D), which were prepared as indicated under
"Experimental Procedures," were incubated with kiKSR-expressing
cells for 1 h prior to the addition of TNF (100 ng/ml) and then
treated for 6 h. The cells were prepared for TUNEL staining as
before (C). The percentage of cells undergoing apoptosis in
a representative experiment is shown (B and
D).

View larger version (55K):
[in a new window]
Fig. 5.
Akt functions as an inhibitor of apoptosis,
whereas p38 promotes apoptosis in cells exposed to TNF. YAMC cells
(A and B) or kiKSR-expressing YAMC cells
(C-E) were treated with TNF for 6 h in the absence or
presence of 1-h pretreatment with wortmannin (100 nM),
LY294002 (10 µM), SB203580 (10 µM), or
SB202190 (10 µM) as indicated. TUNEL staining was used to
identify apoptotic nuclei by peroxidase. The cells were visualized by
differential interference contrast microscopy (A and
C). The percentage of cells undergoing apoptosis from
representative experiments is shown (B and D).
p38 phosphorylation was detected as described in Fig. 3.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
B activation
and IL-8 production (30). However, these Salmonella species
do not alter apoptotic response to cytokine (Fig. 4, B and
C), nor does LGG inhibit NF
B activation (data not shown). We did not detect NF
B activation by either inhibitor of
B
degradation (Fig. 2F) or NF
B p65 subunit nuclear
translocation up to 6 h after LGG treatment (data not shown).
Although we did not specifically study IL-8 secretion in our cells, it
is increased in CaCo2 cells treated with Lactobacillus (38).
A commensal Bifidobacterium strain regulates intestinal cell
gene expression (3) and promotes its own survival within the host (2).
Clearly, the mechanisms of activating intestinal cell signal
transduction pathways by commensal bacteria are relevant to the
maintenance of this important physical and functional mucosal barrier.
B (40),
extracellular ERK1/ERK2/MAP kinase (41), and PI 3-kinase/Akt (42). By
contrast, other members of the MAP kinase family, including SAPK/JNK
and p38 function as pro-apoptotic signals for a number of cell types
(41). KSR is an essential kinase in TNF signal transduction,
determining intestinal epithelial cell fate by regulating the
anti-apoptotic NF
B, ERK/MAP kinase, and Akt pathways (29). However,
neither TNF activation of p38 MAP kinase nor SAPK/JNK is inhibited by
disruption of KSR signaling. Despite blocking all the anti-apoptotic
signals mediated through KSR, LGG still promotes intestinal cell
survival (Fig. 1). This effect appears to require blocking p38 MAP
kinase activation (Fig. 5B), because Akt activation by the
LGG supernatant is insufficient to fully reverse apoptosis (Fig.
1B).
| |
ACKNOWLEDGEMENTS |
|---|
We thank Andrew Neish (Emory University) for S. pullorum and S. typhimurium PhoPc; Valio Ltd. (Helsinki, Finland) for LGG; Sam Wells, Han Liang, Wei Tong, Guinn Wilson, and Mark Frey for excellent technical assistance; the Vanderbilt University Medical Center Imaging Core Research Laboratory (CA68485); and Graham Carpenter, Steve Hanks, and Raymond DuBois for helpful discussions and critical review of the manuscript.
| |
FOOTNOTES |
|---|
* This work was supported by a Children's Digestive Health and Nutrition Foundation/Nestle Nutrition Grant (to F. Y.), National Institutes of Health Grants DK10105 (to F. Y.) and DK56008 (to D. B. P.), and the Vanderbilt University Digestive Disease Research Center (DK58404).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
¶ To whom correspondence should be addressed: Pediatric Gastroenterology, Hepatology, and Nutrition, S4322 MCN, 21st and Garland Ave., Nashville, TN 37232-2576. Tel.: 615-322-7449; Fax: 615-343-8915; E-mail: d-brent.polk@vanderbilt.edu.
Published, JBC Papers in Press, October 21, 2002, DOI 10.1074/jbc.M207050200
| |
ABBREVIATIONS |
|---|
The abbreviations used are:
LGG, Lactobacillus rhamnosus GG;
ERK, extracellular
signal-regulated kinase;
IBD, inflammatory bowel disease;
IFN, interferon;
IL, interleukin;
ki, kinase-inactive;
KSR, kinase
suppressor of Ras;
LGG-cm, LGG conditioned medium;
LGG-s, supernatant recovered from LGG culture broth;
MAP, mitogen activated protein;
NF
B, nuclear factor
B;
PI, phosphoinositide;
SAPK/JNK, stress-activated protein kinase/c-Jun
amino-terminal kinase;
TNF, tumor necrosis factor;
YAMC, young adult
mouse colon;
hk, heat killed;
DAPI, 4,6-diamidino-2-phenylindole;
TUNEL, terminal deoxynucleotidyltransferase-mediated dUTP nick-end
labeling.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Berg, R. D. (1996) Trends Microbiol. 4, 430-435[CrossRef][Medline] [Order article via Infotrieve] |
| 2. | Bry, L., Falk, P. G., Midtvedt, T., and Gordon, J. I. (1996) Science 273, 1380-1383[Abstract] |
| 3. |
Hooper, L. V.,
Wong, M. H.,
Thelin, A.,
Hansson, L.,
Falk, P. G.,
and Gordon, J. I.
(2001)
Science
291,
881-884 |
| 4. |
Lilly, D. M.,
and Stillwell, R. H.
(1965)
Science
147,
747-748 |
| 5. | Kirjavainen, P. V., El-, Nezami, H. S., Salminen, S. J., Ahokas, J. T., and Wright, P. F. (1999) FEMS Immunol. Med. Microbiol. 26, 131-135[CrossRef][Medline] [Order article via Infotrieve] |
| 6. | Gill, H. S., Rutherfurd, K. J., Prasad, J., and Gopal, P. K. (2000) Br. J. Nutr. 83, 167-176[CrossRef][Medline] [Order article via Infotrieve] |
| 7. | Pessi, T., Sutas, Y., Hurme, M., and Isolauri, E. (2000) Clin. Exp. Allergy 30, 1804-1808[CrossRef][Medline] [Order article via Infotrieve] |
| 8. |
Marteau, P. R.,
de Vrese, M.,
Cellier, C. J.,
and Schrezenmeir, J.
(2001)
Am. J. Clin. Nutr.
73,
430S-436S |
| 9. | Gorbach, S. L., Chang, T. W., and Goldin, B. (1987) Lancet 2, 1519[Medline] [Order article via Infotrieve] |
| 10. | Szajewska, H., Kotowska, M., Mrukowicz, J. Z., Armanska, M., and Mikolajczyk, W. (2001) J. Pediatr. 138, 361-365[CrossRef][Medline] [Order article via Infotrieve] |
| 11. | Kalliomaki, M., Salminen, S., Arvilommi, H., Kero, P., Koskinen, P., and Isolauri, E. (2001) Lancet 357, 1076-1079[CrossRef][Medline] [Order article via Infotrieve] |
| 12. |
Shanahan, F.
(2000)
Science
289,
1311-1312 |
| 13. | Fabia, R., Ar'Rajab, A., Johansson, M. L., Andersson, R., Willen, R., Jeppsson, B., Molin, G., and Bengmark, S. (1993) Digestion 54, 248-255[Medline] [Order article via Infotrieve] |
| 14. | Favier, C., Neut, C., Mizon, C., Cortot, A., Colombel, J. F., and Mizon, J. (1997) Dig. Dis. Sci. 42, 817-822[CrossRef][Medline] [Order article via Infotrieve] |
| 15. | Madsen, K. L., Doyle, J. S., Jewell, L. D., Tavernini, M. M., and Fedorak, R. N. (1999) Gastroenterology 116, 1107-1114[CrossRef][Medline] [Order article via Infotrieve] |
| 16. | Schultz, M., Veltkamp, C., Dieleman, L. A., Grenther, W. B., Wyrick, P. B., Tonkonogy, S. L., and Sartor, R. B. (2002) Inflamm. Bowel Dis. 8, 71-80[CrossRef][Medline] [Order article via Infotrieve] |
| 17. | Malin, M., Suomalainen, H., Saxelin, M., and Isolauri, E. (1996) Ann. Nutr. Metab. 40, 137-145[Medline] [Order article via Infotrieve] |
| 18. | Maassen, C. B., van Holten-Neelen, C., Balk, F., den Bak-Glashouwer, M. J., Leer, R. J., Laman, J. D., Boersma, W. J., and Claassen, E. (2000) Vaccine 18, 2613-2623[CrossRef][Medline] [Order article via Infotrieve] |
| 19. |
Miettinen, M.,
Matikainen, S.,
Vuopio-Varkila, J.,
Pirhonen, J.,
Varkila, K.,
Kurimoto, M.,
and Julkunen, I.
(1998)
Infect. Immun.
66,
6058-6062 |
| 20. | Miettinen, M., Vuopio-Varkila, J., and Varkila, K. (1996) Infect. Immun. 64, 5403-5405[Abstract] |
| 21. | Rodrigues, A. C., Cara, D. C., Fretez, S. H., Cunha, F. Q., Vieira, E. C., Nicoli, J. R., and Vieira, L. Q. (2000) J. Appl. Microbiol. 89, 404-414[CrossRef][Medline] [Order article via Infotrieve] |
| 22. | Zamfir, M., Callewaert, R., Cornea, P. C., Savu, L., Vatafu, I., and De Vuyst, L. (1999) J. Appl. Microbiol. 87, 923-931[CrossRef][Medline] [Order article via Infotrieve] |
| 23. | Bernet-Camard, M. F., Lievin, V., Brassart, D., Neeser, J. R., Servin, A. L., and Hudault, S. (1997) Appl. Environ. Microbiol. 63, 2747-2753[Abstract] |
| 24. | Gotteland, M., Cruchet, S., and Verbeke, S. (2001) Aliment Pharmacol. Ther. 15, 11-17[CrossRef][Medline] [Order article via Infotrieve] |
| 25. |
Bernet, M. F.,
Brassart, D.,
Neeser, J. R.,
and Servin, A. L.
(1994)
Gut
35,
483-489 |
| 26. | Breese, E. J., Michie, C. A., Nicholls, S. W., Murch, S. H., Williams, C. B., Domizio, P., Walker-Smith, J. A., and MacDonald, T. T. (1994) Gastroenterology 106, 1455-1466[Medline] [Order article via Infotrieve] |
| 27. | Sartor, R. B. (1995) Gastroenterol. Clin. N. Am. 24, 475-507[Medline] [Order article via Infotrieve] |
| 28. | Iwamoto, M., Koji, T., Makiyama, K., Kobayashi, N., and Nakane, P. K. (1996) J. Pathol. 180, 152-159[CrossRef][Medline] [Order article via Infotrieve] |
| 29. |
Yan, F.,
John, S. K.,
and Polk, D. B.
(2001)
Cancer Res.
61,
8668-8675 |
| 30. |
Neish, A. S.,
Gewirtz, A. T.,
Zeng, H.,
Young, A. N.,
Hobert, M. E.,
Karmali, V.,
Rao, A. S.,
and Madara, J. L.
(2000)
Science
289,
1560-1563 |
| 31. | Kaiser, G. C., and Polk, D. B. (1997) Gastroenterology 112, 1231-1240[CrossRef][Medline] [Order article via Infotrieve] |
| 32. |
Yan, F.,
and Polk, D. B.
(2001)
Cancer Res.
61,
963-969 |
| 33. | Zhang, Y., Yao, B., Delikat, S., Bayuomy, S., Lin, X., Basu, S., McGinley, M., Chan-Hui, P., Lichenstein, H., and Kolesnick, R. (1997) Cell 89, 63-72[CrossRef][Medline] [Order article via Infotrieve] |
| 34. |
Perdigon, G.,
de Macias, M. E.,
Alvarez, S.,
Oliver, G.,
and de Ruiz Holgado, A. A.
(1986)
Infect. Immun.
53,
404-410 |
| 35. |
Tieng, V., Le,
Bouguenec, C.,
du Merle, L.,
Bertheau, P.,
Desreumaux, P.,
Janin, A.,
Charron, D.,
and Toubert, A.
(2002)
Proc. Natl. Acad. Sci. U. S. A.
99,
2977-2982 |
| 36. |
Kirjavainen, P. V.,
ElNezami, H. S.,
Salminen, S. J.,
Ahokas, J. T.,
and Wright, P. F. A.
(1999)
Clin. Diagn. Lab Immunol.
6,
799-802 |
| 37. |
Peranen, J.,
Auvinen, P.,
Vitra, H.,
Wepf, R.,
and Simons, K.
(1996)
J. Cell Biol.
135,
153-167 |
| 38. |
Haller, D.,
Bode, C.,
Hammes, W. P.,
Pfeifer, A. M.,
Schiffrin, E. J.,
and Blum, S.
(2000)
Gut
47,
79-87 |
| 39. | Budd, R. C. (2002) J. Clin. Invest. 109, 437-441[CrossRef][Medline] [Order article via Infotrieve] |
| 40. |
Van Antwerp, D. J.,
Martin, S. J.,
Kafri, T.,
Green, D. R.,
and Verma, I. M.
(1996)
Science
274,
787-789 |
| 41. |
Xia, Z.,
Dickens, M.,
Rainegeaud, J.,
Davis, R. J.,
and Greenberg, M. E.
(1995)
Science
270,
1326-1331 |
| 42. |
Dudek, H.,
Datta, S. R.,
Franke, T. F.,
Birnbaum, M. J.,
Yao, R.,
Cooper, G. M.,
Segal, R. A.,
Kaplan, D. R.,
and Greenberg, M. E.
(1997)
Science
275,
661-665 |
This article has been cited by other articles:
![]() |
C. Guzy, D. Paclik, A. Schirbel, U. Sonnenborn, B. Wiedenmann, and A. Sturm The probiotic Escherichia coli strain Nissle 1917 induces {gamma}{delta} T cell apoptosis via caspase- and FasL-dependent pathways Int. Immunol., July 1, 2008; 20(7): 829 - 840. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Borthakur, R. K. Gill, S. Tyagi, A. Koutsouris, W. A. Alrefai, G. A. Hecht, K. Ramaswamy, and P. K. Dudeja The Probiotic Lactobacillus acidophilus Stimulates Chloride/Hydroxyl Exchange Activity in Human Intestinal Epithelial Cells J. Nutr., July 1, 2008; 138(7): 1355 - 1359. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Seth, F. Yan, D. B. Polk, and R. K. Rao Probiotics ameliorate the hydrogen peroxide-induced epithelial barrier disruption by a PKC- and MAP kinase-dependent mechanism Am J Physiol Gastrointest Liver Physiol, April 1, 2008; 294(4): G1060 - G1069. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Flanagan, Z. Modrusan, J. Cornelius, A. Chavali, I. Kasman, L. Komuves, L. Mo, and L. Diehl Intestinal Epithelial Cell Up-Regulation of LY6 Molecules during Colitis Results in Enhanced Chemokine Secretion J. Immunol., March 15, 2008; 180(6): 3874 - 3881. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Reilly, V. Poylin, M. Menconi, A. Onderdonk, S. Bengmark, and P.-O. Hasselgren Probiotics potentiate IL-6 production in IL-1beta-treated Caco-2 cells through a heat shock-dependent mechanism Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2007; 293(3): R1169 - R1179. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Corthesy, H. R. Gaskins, and A. Mercenier Cross-Talk between Probiotic Bacteria and the Host Immune System J. Nutr., March 1, 2007; 137(3): 781S - 790S. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Chen, E. G. Kokkotou, N. Mustafa, K. R. Bhaskar, S. Sougioultzis, M. O'Brien, C. Pothoulakis, and C. P. Kelly Saccharomyces boulardii Inhibits ERK1/2 Mitogen-activated Protein Kinase Activation Both in Vitro and in Vivo and Protects against Clostridium difficile Toxin A-induced Enteritis J. Biol. Chem., August 25, 2006; 281(34): 24449 - 24454. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Grabig, D. Paclik, C. Guzy, A. Dankof, D. C. Baumgart, J. Erckenbrecht, B. Raupach, U. Sonnenborn, J. Eckert, R. R. Schumann, et al. Escherichia coli Strain Nissle 1917 Ameliorates Experimental Colitis via Toll-Like Receptor 2- and Toll-Like Receptor 4-Dependent Pathways Infect. Immun., July 1, 2006; 74(7): 4075 - 4082. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. B. Ewaschuk, J. W. Walker, H. Diaz, and K. L. Madsen Bioproduction of Conjugated Linoleic Acid by Probiotic Bacteria Occurs In Vitro and In Vivo in Mice J. Nutr., June 1, 2006; 136(6): 1483 - 1487. [Abstract] [Full Text] [PDF] |
||||
![]() |
A-P Bai and Q Ouyang Probiotics and inflammatory bowel diseases. Postgrad. Med. J., June 1, 2006; 82(968): 376 - 382. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. I. Fenton and N. G. Hord Stage matters: choosing relevant model systems to address hypotheses in diet and cancer chemoprevention research Carcinogenesis, May 1, 2006; 27(5): 893 - 902. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Tao, K. A. Drabik, T. S. Waypa, M. W. Musch, J. C. Alverdy, O. Schneewind, E. B. Chang, and E. O. Petrof Soluble factors from Lactobacillus GG activate MAPKs and induce cytoprotective heat shock proteins in intestinal epithelial cells Am J Physiol Cell Physiol, April 1, 2006; 290(4): C1018 - C1030. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. A. Ruiz and D. Haller Functional Diversity of Flavonoids in the Inhibition of the Proinflammatory NF-{kappa}B, IRF, and Akt Signaling Pathways in Murine Intestinal Epithelial Cells J. Nutr., March 1, 2006; 136(3): 664 - 671. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. G. Buret How Stress Induces Intestinal Hypersensitivity Am. J. Pathol., January 1, 2006; 168(1): 3 - 5. [Full Text] [PDF] |
||||
![]() |
A. Sturm, K. Rilling, D. C. Baumgart, K. Gargas, T. Abou-Ghazale, B. Raupach, J. Eckert, Ralf. R. Schumann, C. Enders, U. Sonnenborn, et al. Escherichia coli Nissle 1917 Distinctively Modulates T-Cell Cycling and Expansion via Toll-Like Receptor 2 Signaling Infect. Immun., March 1, 2005; 73(3): 1452 - 1465. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Shanahan Physiological Basis for Novel Drug Therapies Used to Treat the Inflammatory Bowel Diseases I. Pathophysiological basis and prospects for probiotic therapy in inflammatory bowel disease Am J Physiol Gastrointest Liver Physiol, March 1, 2005; 288(3): G417 - G421. [Abstract] [Full Text] [PDF] |
||||